Hikal Ltd.

What Hikal Ltd. does

Hikal Ltd. is an Indian publicly-listed (NSE/BSE ticker: HIKAL) fine chemicals and contract development and manufacturing organization (CDMO) founded in 1988 and headquartered in Navi Mumbai, with operations spanning pharmaceuticals, crop protection, and specialty chemicals. The company operates five manufacturing facilities — Jigani Units 1 and 2 (Karnataka), Panoli (Gujarat), Mahad (Maharashtra), and Taloja (Maharashtra) — with a combined reactor capacity of 4,100 M3, supported by a Research and Technology centre in Pune housing 250+ post-graduates, 26 PhDs, and an HPAPI laboratory. Hikal manufactures active pharmaceutical ingredients (APIs), intermediates, animal health products, and crop protection chemicals (insecticides, fungicides, herbicides, biocides) primarily for global pharmaceutical innovator and crop protection companies, with additional specialty chemical custom manufacturing.

The company generates revenue via custom synthesis contracts and CDMO services priced on a project-by-project, multi-year basis with global enterprise customers in pharma, crop protection, biotech, agrochemicals, and specialty chemicals. Pharmaceuticals and crop protection are the primary revenue divisions; animal health (entered 2007) and specialty chemicals are smaller. Hikal invests 4–5% of sales in R&D (INR 806M in FY24, with 13 patent applications filed), and emphasizes US FDA approvals, green chemistry (61.7% renewable energy in FY24), and ESG practices. Recent strategic initiatives include Project Pinnacle 2.0 (operational excellence) and a new Animal Health manufacturing facility at Panoli; however, the company has experienced revenue and margin decline from FY23 to FY26 and faces regulatory headwinds from a USFDA warning letter on its Jigani facility issued in August 2025.

Name

Hikal Ltd.

Legal name

HIKAL Ltd.

Website

https://hikal.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Hikal Ltd. is an Indian publicly-listed CDMO founded in 1988 that manufactures APIs, intermediates, crop protection chemicals, and specialty chemicals for global pharmaceutical and agrochemical innovator companies across five manufacturing facilities and a Pune R&D centre.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO and Crop Protection Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pesticide and Other Agricultural Chemical Manufacturing (32532), Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253)

SIC

Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Custom Synthesis & Technical Active Ingredient (AI) Manufacturing (intermediates, actives) (AFABAIAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Pharmaceutical contract manufacturing
• Active pharmaceutical ingredients
• Crop protection chemicals
• Custom synthesis services
• Animal health manufacturing

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Division: Manufacturing and sale of APIs (Active Pharmaceutical Ingredients) and intermediates for human health and animal health. Includes contract development and manufacturing services (CDMO) for global pharmaceutical companies.
2. Crop Protection Division: Manufacturing and sale of insecticides, fungicides, herbicides, biocides, and intermediates for agricultural industry.
3. Specialty Chemicals: Custom manufacturing solutions for specialty chemicals industry.
4. Contract Research Services: R&D and contract research services provided to pharmaceutical and life sciences companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Hikal manufactures and supplies active pharmaceutical ingredients (APIs), advanced intermediates, and crop protection chemicals (insecticides, fungicides, herbicides, biocides) for global pharmaceutical, agrochemical, and specialty chemicals companies. The company also provides contract development and manufacturing (CDMO) services, animal health APIs/intermediates, and custom synthesis solutions through five manufacturing facilities and a dedicated Research & Technology centre.

Product overview

Hikal Ltd. is a diversified fine chemical company operating across Pharmaceuticals, Crop Protection, and Specialty Chemicals divisions. The company offers a portfolio of products including active pharmaceutical ingredients (APIs), intermediates, contract development and manufacturing (CDMO) services, animal health products, crop protection chemicals (insecticides, fungicides, herbicides, biocides), and specialty chemicals. The Pharmaceuticals Division provides APIs, intermediates, and CDMO services for human and animal health; the Crop Protection Division delivers insecticides, fungicides, herbicides, and intermediates; the Specialty Chemicals Division offers custom manufacturing solutions. The Research & Technology center supports product development across all divisions, and Project Pinnacle 2.0 serves as the company's strategic transformation initiative.

Differentiator

Problem solved

Functional benefit

Brands

• Project Pinnacle: Strategic transformation initiative launched in 2022 to achieve growth targets and operational excellence.
• HiBEX

Products and services

• Pharmaceuticals Division Provides active pharmaceutical ingredients (APIs), intermediates, contract development and manufacturing (CDMO) services, and animal health products for global pharmaceutical companies serving human and animal health applications.
• Crop Protection Division Provides crop protection products including insecticides, fungicides, herbicides, biocides, and intermediates for global agricultural industry companies.
• Specialty Chemicals Delivers custom manufacturing solutions for the specialty chemicals industry serving various sectors with tailored chemical products.
• Research & Technology Services R&D services, process development, and innovation support for pharmaceuticals, crop protection, and specialty chemicals divisions, backed by a Scientific Advisory Board of globally renowned chemists.
• APIs and Intermediates Manufacturing of active pharmaceutical ingredients and advanced intermediates for global pharmaceutical innovator companies, including complex chiral chemistry and conventional synthesis capabilities.
• Contract Development & Manufacturing (CDMO) Contract research and custom synthesis services for pharmaceutical companies, supporting scale-up from gram to tonne quantities with end-to-end development and manufacturing capabilities.
• Animal Health APIs and Intermediates Animal health APIs and intermediates for farm and companion animal segments, manufactured from GMP-compliant facilities including 10+ animal health focused APIs and 4+ existing relationships with animal health innovators.

Quantifiable outcome

• Revenue of INR 17,870 million in FY24
• +6 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators20 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Divi's Laboratories: Indian-listed API manufacturer and CDMO with similar custom synthesis and intermediates offering for global pharma customers. Direct competitor in the small-molecule API and intermediates CDMO space, with comparable USFDA footprint.
• Laurus Labs: Indian-listed API, intermediates, and CDMO peer serving global pharmaceutical innovators. Comparable business model around custom synthesis, generic APIs, and contract manufacturing with overlapping customer base.
• Syngene International: India-based CRO and CDMO providing contract research and manufacturing services to global pharma and biotech. Closely comparable in CDMO positioning, scientific talent base, and global innovator customer set.
• Jubilant Pharmova: Indian-listed CDMO with API, intermediates, and radiopharmaceuticals manufacturing. Comparable in CDMO service offering, regulatory footprint, and customer profile of global pharmaceutical companies.
• Piramal Pharma Solutions: Contract development and manufacturing arm of Piramal Group offering API and intermediates CDMO services globally. Comparable in integrated CDMO service model targeting innovator pharma customers.
• Suven Pharmaceuticals: Indian CDMO focused on niche APIs, intermediates, and custom synthesis for global pharma. Comparable in CDMO service mix and customer base of innovator and specialty pharmaceutical companies.
• Navin Fluorine International: Indian specialty fluorochemicals manufacturer serving pharma and crop protection customers. Comparable in specialty chemicals custom manufacturing serving overlapping end-markets to Hikal's specialty chemicals and crop protection divisions.

Broad incumbents

• Atul Ltd: Diversified Indian chemical manufacturer with operations spanning specialty chemicals, crop protection, and pharma intermediates. Overlaps with Hikal's specialty chemicals and crop protection business as a broader incumbent in Indian contract/specialty chemicals.
• Aurobindo Pharma: Large Indian generic and API manufacturer with vertically integrated manufacturing. Operates in the same API space as Hikal but with greater downstream formulation exposure; comparable as a broad incumbent in Indian pharmaceutical manufacturing.
• BASF: Global chemical conglomerate with crop protection, intermediates, and custom synthesis businesses. Relevant as a broad incumbent in both crop protection active ingredients and pharmaceutical intermediates where Hikal competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hikal-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hikal Ltd.